- REMUNE(R) and IR103 Development on Track -
CARLSBAD, Calif., July 27 /PRNewswire-FirstCall/ -- The Immune Response
Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming
a leading immune-based therapy company in HIV and multiple sclerosis (MS),
presented research results at the International Congress of Immunology in
Montreal demonstrating that IR103 generated robust HIV-1 specific immune
responses. IR103 combines the Company's patented HIV-1 Immunogen with the
immunostimulatory oligonucleotide adjuvant Amplivax(TM).
"We are pleased with the promising results and clinical progress of both
HIV product candidates, REMUNE(R) and IR103," said John N. Bonfiglio, Ph.D.,
Chief Executive Officer of The Immune Response Corporation. "The REMUNE(R)
Phase II trials in Italy and Spain and the IR103 clinical trial in Canada and
the UK are all on track and we are looking forward to seeing the data."
Investigators presented a preclinical study in which mice immunized
subcutaneously with IR103 showed significantly enhanced production of a number
of key markers of HIV-1 specific immune responses. Importantly, the study
demonstrated that IR103 increases HIV-1 specific immune responses when
administered with and without Incomplete Freund's Adjuvant (IFA).
Amplivax(TM) was developed by Hybridon, Inc. (Amex: HBY) and has been
licensed to The Immune Response Corporation.
About The Immune Response Corporation
The Immune Response Corporation (Nasdaq: IMNR) is a biopharmaceutical
company dedicated to becoming a leading immune-based therapy company in HIV
and multiple sclerosis (MS). The Company's HIV products are based on its
patented whole-killed virus technology, co-invented by Company founder Dr.
Jonas Salk, to stimulate HIV immune responses. REMUNE(R), currently in Phase
II clinical trials, is being developed as a first-line treatment for people
with early-stage HIV. The Company has initiated development of a new
immune-based therapy, IR103, which incorporates a second-generation
immunostimulatory oligonucleotide adjuvant.
The Immune Response Corporation is also developing an immune-based therapy
for MS, NeuroVax(TM), which is currently in Phase II and has shown potential
therapeutic value for this difficult-to-treat disease.
Please visit The Immune Response Corporation on the World Wide Web at
http://www.imnr.com
This news release contains forward-looking statements. Forward-looking
statements are often signaled by forms of words such as should, could, will,
might, plan, projection, forecast, expect, guidance, potential and developing.
Actual results could vary materially from those expected due to a variety of
risk factors, including whether the Company will continue as a going concern
and successfully raise proceeds from financing activities sufficient to fund
operations and additional clinical trials of REMUNE(R), NeuroVax(TM) or IR103,
the uncertainty of successful completion of any such clinical trials, the fact
that the Company has not succeeded in commercializing any drug, the risk that
REMUNE(R), NeuroVax(TM) or IR103 might not prove to be effective as either a
therapeutic or preventive vaccine, whether future trials will be conducted and
whether the results of such trials will coincide with the results of
REMUNE(R), NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical
trials. These risks, among others, are set forth in The Immune Response
Corporation's SEC filings including, but not limited to, its Annual Report on
Form 10-K for the year ended December 31, 2003, and any subsequent Quarterly
Reports on Form 10-Q. The Company undertakes no obligation to update the
results of these forward-looking statements to reflect events or circumstances
after today or to reflect the occurrence of unanticipated events.
REMUNE(R) is a registered trademark of The Immune Response Corporation.
NeuroVax(TM) is a trademark of The Immune Response Corporation.
For further information, please contact: Media, Laura Silver of Sam Brown
Inc., +1-310-551-9940, silver@sambrown.com, or Investor Relations, Kathy
Waller of Financial Relations Board, +1-312-266-7800,
kwaller@financialrelationsboard.com, both for The Immune Response Corporation;
or Michael K. Green, Chief Financial Officer of The Immune Response
Corporation, +1-760-431-7080, info@imnr.com.
SOURCE The Immune Response Corporation
 back to top
Related links:
http://www.imnr.com
CONTACT:
Media, Laura Silver of Sam Brown Inc.,
+1-310-551-9940, silver@sambrown.com; or Investor Relations,
Kathy Waller of Financial Relations Board, +1-312-266-7800,
kwaller@financialrelationsboard.com; or Michael K. Green, Chief
Financial Officer of The Immune Response Corporation,
+1-760-431-7080, info@imnr.com
|
